| Literature DB >> 35622597 |
Pierrick Gouel1, Clémence Mahana Iti Gatti2, Luc de Haro3, Alice Liautaud4, Jérôme Langrand4, Denis Boucaud-Maitre5.
Abstract
Tetrodotoxin is one of the most potent neurotoxins in the aquatic world. This review of published and unpublished reports aims to describe the poisoning cases that have occurred in mainland France and overseas territories. Six articles were included, with 13 poisoning events, individuals or collective (number (n) = 53 patients). Moreover, 13 unpublished poisoning events from toxicovigilance networks were found (n = 17). All cases happened in overseas territories: French Guyana (n = 7), New Caledonia (n = 11), Reunion (n = 35) and French Polynesia (n = 17). The median age was 36 years. The most frequent signs were neurological (81.8%), digestive (54.5%) and general (52.3%). Three cases of dysgueusia and nine cases of urogenital discomfort were observed in French Polynesia. Twelve severe cases were reported, including seven deaths. Only three events (11.5%) were documented by a tetrodotoxin assay. Two families of fish accounted for 91.6% of the poisonings: 33.3% due to the Diodontidae family and 58.3% to the Tetraodontidae family. Although rare, information and collection campaigns on tetrodotoxin poisoning are, therefore, essential.Entities:
Keywords: France; marine toxicology; review; tetrodotoxin
Mesh:
Substances:
Year: 2022 PMID: 35622597 PMCID: PMC9146393 DOI: 10.3390/toxins14050351
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 5.075
Figure 1PRISMA Flow-chart of TTX poisonings in Mainland France and French Overseas Territories (CAP = Centre Antipoison or Poisoning Center).
Figure 2Geographic distribution of the cases.
Figure 3TTX poisonings reported in France by decades.
Most frequent clinical signs and symptoms (more than 10% of the patients) of the TTX poisonings in Mainland France and French Overseas Territories (n = 44).
| Signs and Symptoms | Number of Cases ( | |
|---|---|---|
|
|
| |
| • Paresthesia | 33 (75.0%) | |
| • Sensitivity disorder | 15 (34.1%) | |
| • Vertigo | 11 (25.0%) | |
| • Ataxia | 10 (22.7%) | |
| • Dysarthria | 8 (18.2%) | |
| • Headache | 7 (15.9%) | |
| • Tetraparesis | 7 (15.9%) | |
| • Reflex disorder | 6 (13.6%) | |
| • Mydriasis | 5 (11.4%) | |
|
| 24 (54.5%) | |
| • Nausea | 16 (36.4%) | |
| • Vomiting | 10 (22.7%) | |
| • Abdominal pain | 7 (15.9%) | |
|
| 23 (52.3%) | |
| • Muscle weakness | 16 (36.4%) | |
| • Arthralgias, myalgias | 6 (13.6%) | |
| • Shivering | 6 (13.6%) | |
| • Others | 9 (20.4%) | |
|
| 8 (18.2%) | |
| • Bradycardia | 6 (13.6%) | |
|
| 7 (15.9%) | |
|
| 7 (15.9%) | |
| • Pruritus | 5 (11.4%) | |
Figure 4Incriminated fish families in tetrodotoxin poisoning in France.
List of clinical signs and symptoms of the TTX poisonings in Mainland France and French Overseas Territories (n = 38 symptomatic patients).
| Number of Cases | Percentage/Category | Percentage/Total | ||
|---|---|---|---|---|
|
|
|
| ||
| Paresthesia |
| 91.7% | 86.8% | |
| Distal or of the extremities paresthesias | 21 | 58.3% | 55.3% | |
| Peribuccal paresthesia | 10 | 27.8% | 26.3% | |
| Labial paresthesia | 4 | 11.1% | 10.5% | |
| Buccal paresthesia | 3 | 8.3% | 7.9% | |
| Dermatologic paresthesia | 3 | 8.3% | 7.9% | |
| Sensitivity disorder | 15 | 41.7% | 39.5% | |
| “Touch disorder” | 9 | 25.0% | 23.7% | |
| Allodynia | 6 | 16.7% | 15.8% | |
| Superficial sensitivity disorder | 3 | 8.3% | 7.9% | |
| Deep sensitivity disorder | 2 | 5.6% | 5.3% | |
| Ataxia | 10 | 27.8% | 26.3% | |
| Walking disorder | 4 | 11.1% | 10.5% | |
| Coordination disorder | 3 | 8.3% | 7.9% | |
| Equilibrium disorder | 2 | 5.6% | 5.3% | |
| Reflex disorders | 6 | 16.7% | 15.8% | |
| Areflexia | 5 | 13.9% | 13.2% | |
| Corneal reflex abolition | 1 | 2.8% | 2.6% | |
| Mydriasis | 5 | 13.9% | 13.2% | |
| Anisocoria | 1 | 2.8% | 2.6% | |
| Vertigo | 11 | 30.6% | 28.9% | |
| Dysarthria | 8 | 22.2% | 21.1% | |
| Tétraparésie | 7 | 19.4% | 18.4% | |
| Headache | 7 | 19.4% | 18.4% | |
| Vision disorder | 3 | 8.3% | 7.9% | |
| Nystagmus | 2 | 5.6% | 5.3% | |
| Vestibular syndrom | 2 | 5.6% | 5.3% | |
| Coma | 2 | 5.6% | 5.3% | |
|
|
|
| ||
| Nausea | 16 | 66.7% | 42.1% | |
| Vomiting | 10 | 41.7% | 26.3% | |
| Diarrhea | 6 | 25.0% | 15.8% | |
| Hypersialorrhea | 3 | 12.5% | 7.9% | |
| Pain | 7 | 29.2% | 18.4% | |
| Epigastralgic | 4 | 16.7% | 10.5% | |
| Abdominal | 3 | 12.5% | 7.9% | |
|
|
|
| ||
| Muscular weakness | 16 | 69.6% | 42.1% | |
| Pain | 6 | 26.1% | 15.8% | |
| Arthralgias | 4 | 17.4% | 10.5% | |
| Myalgias | 2 | 8.7% | 5.3% | |
| Shiverings | 6 | 26.1% | 15.8% | |
| Faintness | 4 | 17.4% | 10.5% | |
| Hypothermia | 2 | 8.7% | 5.3% | |
| Drowsiness | 2 | 8.7% | 5.3% | |
| Anxiety | 1 | 4.3% | 2.6% | |
| Others | 9 | 39.1% | 23.7% | |
| Uro-genital discomfort | 3 | 13.0% | 7.9% | |
| Buccal/throat burns/dysgueusia | 8 | 34.8% | 21.1% | |
|
|
|
| ||
| Bradycardia | 6 | 75.0% | 15.8% | |
| Hypotension | 4 | 50.0% | 10.5% | |
| Tachycardia | 1 | 12.5% | 2.6% | |
|
|
|
| ||
| Dyspnea | 4 | 57.1% | 10.5% | |
| Respiratory distress | 2 | 28.6% | 5.3% | |
| Desaturation | 2 | 28.6% | 5.3% | |
| Bradypnea | 2 | 28.6% | 5.3% | |
|
|
|
| ||
| Pruritus | 5 | 71.4% | 13.2% | |
| Sweating/excessive sweating | 3 | 42.9% | 7.9% | |